Treatment of the bone marrow failure in Fanconi anemia patients with danazol

Blood Cells, Molecules, and Diseases

Volumn 48, Issue 2, 2012, Pages 128-131

  Scheckenbach, Kathrin ^a   Morgan, Mary ^b   Filger Brillinger, Judith ^c   Sandmann, Matthias ^d   Strimling, Bruce ^e   Scheurlen, Wolfram ^f   Schindler, Detlev ^c   Göbel, Ulrich ^a   Hanenberg, Helmut ^a,g  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Petrus Krankenhaus   (Germany)

^e Crescent Medical Clinic   (United States)

^f Cnopf f sche Kinderklinik   (Germany)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen; Bone marrow failure; Danazol; Fanconi anemia; Treatment

Indexed keywords

DANAZOL; HEMOGLOBIN; OXYMETHOLONE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; BONE MARROW DEPRESSION; CHILD; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONGENITAL MALFORMATION; DRUG DOSE REDUCTION; FANCONI ANEMIA; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MALE; MYELODYSPLASTIC SYNDROME; OFF LABEL DRUG USE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SQUAMOUS CELL CARCINOMA; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; BLOOD CELL COUNT; BONE MARROW; CHILD; CHILD, PRESCHOOL; DANAZOL; ESTROGEN ANTAGONISTS; FANCONI ANEMIA; FEMALE; HUMANS; MALE; MUTATION; YOUNG ADULT;

EID: 84856402751     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.11.006     Document Type: Article

References (38)

1. Kutler D.I., Singh B., Satagopan J., et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003, 101:1249-1256.
2. Neveling K., Endt D., Hoehn H., Schindler D. Genotype-phenotype correlations in Fanconi anemia. Mutat. Res. 2009, 668:73-91.
3. D'Andrea A.D. Susceptibility pathways in Fanconi's anemia and breast cancer. N. Engl. J. Med. 2010, 362:1909-1919.
4. Cybulski K.E., Howlett N.G. FANCP/SLX4: a Swiss Army knife of DNA interstrand crosslink repair. Cell Cycle 2011, 10:1757-1763.
5. Wagner J.E., Eapen M., Macmillan M.L., et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2007, 109:2256-2262.
6. Huck K., Hanenberg H., Nurnberger W., et al. Favourable long-term outcome after matched sibling transplantation for Fanconi-anemia (FA) and in vivo T-cell depletion. Klin. Pädiatr. 2008, 220:147-152.
7. MacMillan M.L., Hughes M.R., Agarwal S., Daley G.Q. Cellular therapy for Fanconi anemia: the past, present, and future. Biol. Blood Marrow Transplant. 2011, 17:S109-S114.
8. Stepensky P., Shapira M.Y., Balashov D., et al. Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning. Biol. Blood Marrow Transplant. 2011, 1282-1288.
9. Shahidi N.T., Diamond L.K. Testosterone-induced remission in aplastic anemia of both acquired and congenital types. Further observations in 24 cases. N. Engl. J. Med. 1961, 264:953-967.
10. Velazquez I., Alter B.P. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am. J. Hematol. 2004, 77:257-267.
11. Vercellini P., Somigliana E., Vigano P., et al. Endometriosis: current therapies and new pharmacological developments. Drugs 2009, 69:649-675.
12. Zuraw B.L. Clinical practice. Hereditary angioedema. N. Engl. J. Med. 2008, 359:1027-1036.
13. Chuhjo T., Yamazaki H., Omine M., Nakao S. Danazol therapy for aplastic anemia refractory to immunosuppressive therapy. Am. J. Hematol. 2008, 83:387-389.
14. Jaime-Perez J.C., Colunga-Pedraza P.R., Gomez-Ramirez C.D., et al. Danazol as first-line therapy for aplastic anemia. Ann. Hematol. 2011, 90:523-527.
15. Hanenberg H., Batish S.D., Pollok K.E., et al. Phenotypic correction of primary Fanconi anemia T cells from patients with retroviral vectors as a diagnostic tool. Exp. Hematol. 2002, 30:410-420.
16. Chandra S., Levran O., Jurickova I., et al. A rapid method for retrovirus-mediated identification of complementation groups in Fanconi anemia patients. Mol. Ther. 2005, 12:976-984.
17. Auerbach A.D., Greenbaum J., Pujara K., et al. Spectrum of sequence variation in the FANCG gene: an International Fanconi Anemia Registry (IFAR) study. Hum. Mutat. 2003, 21:158-168.
18. Levran O., Diotti R., Pujara K., et al. Spectrum of sequence variations in the FANCA gene: an International Fanconi Anemia Registry (IFAR) study. Hum. Mutat. 2005, 25:142-149.
19. Sims A.E., Spiteri E., Sims R.J., et al. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat. Struct. Mol. Biol. 2007, 14:564-567.
20. Futaki M., Yamashita T., Yagasaki H., et al. The IVS4 + 4 A to T mutation of the Fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients. Blood 2000, 95:1493-1498.
21. Soulier J., Leblanc T., Larghero J., et al. Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood 2005, 105:1329-1336.
22. Davies S.M., Radloff G.A., Defor T.E., et al. GST genotype may modify clinical phenotype in patients with Fanconi anaemia. Br. J. Haematol. 2005, 131:118-122.
23. Shahidi N.T., Diamond L.K. Testosterone-induced remission in aplastic anemia. AMA J. Dis. Child. 1959, 98:293-302.
24. Calado R.T., Yewdell W.T., Wilkerson K.L., et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 2009, 114:2236-2243.
25. Chabannon C., Molina L., Pegourie-Bandelier B., et al. A review of 76 patients with myelodysplastic syndromes treated with danazol. Cancer 1994, 73:3073-3080.
26. Olsen C.M., Green A.C., Nagle C.M., et al. Epithelial ovarian cancer: testing the 'androgens hypothesis'. Endocr. Relat. Cancer 2008, 15:1061-1068.
27. Bork K., Bygum A., Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann. Allergy Asthma Immunol. 2008, 100:153-161.
28. Letchumanan P., Thumboo J. Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review. Semin. Arthritis Rheum. 2011, 40:298-306.
29. Touraine R.L., Bertrand Y., Foray P., Gilly J., Philippe N. Hepatic tumours during androgen therapy in Fanconi anaemia. Eur. J. Pediatr. 1993, 152:691-693.
30. Guardiola P., Pasquini R., Dokal I., et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood 2000, 95:422-429.
31. Kumar A.R., Wagner J.E., Auerbach A.D., et al. Fatal hemorrhage from androgen-related hepatic adenoma after hematopoietic cell transplantation. J. Pediatr. Hematol. Oncol. 2004, 26:16-18.
32. Kopic S., Eirich K., Schuster B., et al. Hepatoblastoma in a 4-year-old girl with Fanconi anaemia. Acta Paediatr. 2011, 100:780-783.
33. Farkas H., Varga L., Szeplaki G., et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007, 120:e713-e722.
34. Farkas H., Czaller I., Csuka D., et al. The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study. Eur. J. Clin. Pharmacol. 2010, 66:419-426.
35. Gao W., Dalton J.T. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov. Today 2007, 12:241-248.
36. Wijker M., Morgan N.V., Herterich S., et al. Heterogeneous spectrum of mutations in the Fanconi anaemia group A gene. Eur. J. Hum. Genet. 1998, 7:52-59.
37. Strathdee C.A., Gavish H., Shannon W.R., Buchwald M. Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 1992, 356:763-767.
38. Gibson R.A., Morgan N.V., Goldstein L.H., et al. Novel mutations and polymorphisms in the Fanconi anemia Group C gene. Hum. Mutat. 1996, 8:140-148.